Ozempic (semaglutide SC once-weekly) / Novo Nordisk - LARVOL DELTA

Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles (Business Standard) - "The starting price for the 0.25 mg dosage is set at ₹2,200 per week. Higher doses carry proportionately higher costs, reflecting Novo Nordisk’s global pricing strategy adapted to the Indian market."

Launch non-US • Obesity • Type 2 Diabetes Mellitus

Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. (PubMed, Diabetes Care) - P3 | "In people with T2D and ASCVD and/or CKD but with overall mostly preserved eGFR, orally administered semaglutide, compared with placebo, did not significantly reduce adverse kidney outcomes but did slow the decline in eGFR."

Journal • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

The unseen risk of Ozempic: NAION and vision damage. (PubMed, Ann Med Surg (Lond)) - "The FDA issued a warning regarding counterfeit and compounded products while approving semaglutide for weight loss under the Wegovy® brand. Unsupervised usage and problems with diabetes accessibility raise ethical questions."

Journal • Diabetes • Metabolic Disorders • Obesity • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Type 2 Diabetes Mellitus

A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes (clinicaltrials.gov) - P3 | N=264 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SynergyRx is a telemedicine platform offering online GLP-1 prescriptions including semaglutide and tirzepatide for eligible adults seeking medically supervised weight management. (Newswire) - "The service provides virtual consultations with licensed healthcare providers, home medication delivery, 24/7 patient support with provider access included, and transparent self-pay pricing with current promotional packages starting at $200 plus free expedited shipping as of November 2025. The platform currently operates across all 50 U.S. states, subject to state telehealth and prescribing regulations, and reports serving more than 50,000 patients as of late 2025."

Commercial • Obesity

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea (clinicaltrials.gov) - P=N/A | N=600 | Not yet recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Nov 2026 ➔ May 2027

Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Regulator releases new safety warnings for weight loss and diabetes drugs including Ozempic, Wegovy and Mounjaro (News.com.au) - "The safety alert issued by the regulator on Monday details links to two separate safety issues; the potential risk of suicidal thoughts, and reduced effectiveness of oral contraception...It relates to GLP-1 and dual GIP/GLP-1 receptor agonists which are primarily prescribed to manage type 2 diabetes and obesity, and are marketed in Australia as Ozempic (semaglutide) Wegovy (semaglutide), Saxenda (liraglutide), Trulicity (dulaglutide) and Mounjaro (tirzepatide)."

Non-US regulatory • Obesity • Type 2 Diabetes Mellitus

WHO backs GLP-1 treatments to tackle obesity epidemic (CTV News) - "A new generation of appetite-suppressing drugs called GLP-1 agonists -- which includes blockbuster brands Ozempic and Mounjaro -- has become massively popular in recent years. On Monday, the United Nations health agency issued its first guidelines on how such drugs could be used as a key tool for treating obesity in adults as a chronic, relapsing disease....The new guidelines are calling for GLP-1 therapies to be used by adults, excluding pregnant women, ]for the long-term treatment of obesity'. WHO highlighted that while the efficacy of the therapies in treating obesity was 'evident', more data was needed on efficacy and safety over longer periods."

Clinical guideline • Obesity

REALISED: Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes (clinicaltrials.gov) - P=N/A | N=209 | Completed | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Completed

Real-world evidence • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - P2 | N=142 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Pain • Peripheral Neuropathic Pain • Type 2 Diabetes Mellitus

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary (clinicaltrials.gov) - P=N/A | N=470 | Recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Sep 2025 ➔ Mar 2026 | Trial primary completion date: Sep 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Novo Nordisk gears up for December Ozempic launch in India (The Hindu Business Line)

Launch non-US • Type 2 Diabetes Mellitus

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. (PubMed, Hypertension) - P3 | "Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo. CagriSema presents clinically relevant reductions in BP across a wide range of participant subgroups, including those with resistant hypertension. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05567796."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity

Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial. (PubMed, JAMA Psychiatry) - P4 | "To evaluate the efficacy of adjunctive semaglutide on glycemic control, weight-associated outcomes, and cardiometabolic risk factors in individuals with schizophrenia spectrum disorders receiving clozapine or olanzapine and exhibiting early glycemic abnormalities. These findings support the use of GLP-1RAs as a potential early intervention strategy to reduce cardiometabolic risk in this vulnerable population. ClinicalTrials.gov Identifier: NCT04892199."

Clinical • Journal • Cardiovascular • CNS Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Psychiatry • Schizophrenia • Type 2 Diabetes Mellitus

Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison (Cureus) - "A total of 100 participants (58 tirzepatide, 42 semaglutide; median age 27 years) were included, with 87 (87%) being female. Baseline BMI was higher in the tirzepatide group (36.6±4.77 vs. 32.3±3.55 kg/m²; p<0.001). Both drugs produced significant weight loss, with tirzepatide achieving greater reductions than semaglutide (8.53±4.10 vs. 6.85±3.38 kg; p=0.033). Clinically meaningful weight loss (≥5%) was observed in 89 (89%) of participants, and ≥10% loss in 33 (33%), with higher proportions in the tirzepatide group."

Retrospective data • Obesity

Incretin receptor agonism during pregnancy: implications for mother and baby. (PubMed, Clin Sci (Lond)) - "However, recent emerging case reports of human pregnancies where exposure to GLP1RAs has occurred through unplanned pregnancies suggest no harm to the fetus. Given both the potential for GLP1RAs to improve health outcomes in pregnant women with obesity and GDM, and the rapidly rising incidence of fetal exposure, we review the current literature base on the effects of semaglutide use in pregnancy on maternal and offspring health and explore potential broader impacts of use of these agents during the perinatal period based on their known site of action."

Journal • Review • Diabetes • Genetic Disorders • Gestational Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

REIMAGINE 3: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin (clinicaltrials.gov) - P3 | N=274 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • LEP • LEPR

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo (clinicaltrials.gov) - P2 | N=626 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • CST3

PIONEER REAL Saudi Arabia: A multicentre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia. (PubMed, Diabetes Obes Metab) - "This real-world population of adults with T2D in Saudi Arabia experienced clinically significant reductions in HbA1c and BW, increased treatment satisfaction and a favourable safety profile, consistent with previously published PIONEER REAL studies."

Journal • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. (PubMed, Diabetes Care) - P3 | "These novel data support semaglutide 2.4 mg as an efficacious obesity treatment in adolescents with obesity and advance its application by showing associated improvements in insulin sensitivity, glycemic measures, ALT, and other cardiometabolic risk factors."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Medicare announces price cuts for…prescription drugs, including Ozempic (MSN News) - "The Centers for Medicare and Medicaid Services on Tuesday announced lower prices on 15 costly prescription drugs under Medicare, including Ozempic and Wegovy....Ozempic, Rybelsus and Wegovy, for Type 2 diabetes and weight loss: $274 negotiated price, down from the $959 list price. (Negotiated prices for higher doses of Wegovy are $385.)."

Commercial • Obesity • Type 2 Diabetes Mellitus

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. (PubMed, Diabetes Obes Metab) - "The totality of data analysed did not suggest an association between liraglutide or semaglutide use and thyroid cancer risk in adults."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus

Xevant Expands Ivim at Work and Introduces New Lower Pricing on Wegovy and Ozempic for Employers Nationwide (Businesswire) - "The update introduces pricing starting at $199 per month for the first two doses of Wegovy and Ozempic (0.25 mg and 0.5 mg) for new patients, followed by a standard continuation price of $349 per month for continued therapy with Wegovy and Ozempic. All pricing reflects U.S. pharmacy supply and full clinical oversight through the Ivim at Work program. The changes strengthen Xevant’s position as a leader in enabling evidence-based weight-loss therapy at the lowest viable cost for employer health plans."

Pricing • Obesity

Interest in Facial Volume Restorative Procedures With the Rise in "Ozempic Face": A Google Trends Analysis. (PubMed, Plast Reconstr Surg Glob Open) - "This study highlights the growing role of facial aesthetic procedures in the care of GLP-1RA users. Our findings underscore the need for greater clinician education and continued research on the most effective and optimal methods for approaching these side effects."

Journal • Aesthetic Medicine • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Study shows Ozempic could help dialysis patients qualify for kidney transplants (Medical Xpress) - "'These results are very encouraging,' said study author Krista Lentine, MD, PhD...'Semaglutide provides a promising, non-surgical option to support weight reduction and help more patients become eligible for transplant.'"

Media quote